All In Biotech

Drug Trial Radar · NCT04710576

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingResults posted on the registryPivotal-lookingRandomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

296

Planned (sponsor's estimate)

Start

Mar 4, 2021

Primary completion

Apr 7, 2023

Study completion Sep 2027

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Conditions

  • Chronic Graft-versus-host-disease

Interventions

  • AxatilimabDrug

    Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)Time frame: First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)

Locations

121 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Children's of Alabama

    Birmingham, Alabama · Completed

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Active not recruiting

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles (UCLA) - Medical Center

    Los Angeles, California · Completed

  • Stanford Cancer Center

    Stanford, California · Active not recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Active not recruiting

  • University of Florida (UF)

    Gainesville, Florida · Completed

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Active not recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Completed

  • Moffitt

    Tampa, Florida · Active not recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Active not recruiting

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois · Recruiting

  • Indiana University Health Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Active not recruiting

  • Franciscan Health Indianapolis

    Indianapolis, Indiana · Completed

  • Tulane University Medical Center

    New Orleans, Louisiana · Completed

  • Johns Hopkins Kimmel Cancer Center

    Baltimore, Maryland · Completed

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts · Active not recruiting

  • University of Michigan

    Ann Arbor, Michigan · Active not recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Completed

  • University of Minnesota

    Minneapolis, Minnesota · Completed

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Active not recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Active not recruiting

  • Weill Medical College of Cornell University

    New York, New York · Active not recruiting

  • Stony Brook University Medical Center

    Stony Brook, New York · Active not recruiting

  • Wake Forest

    Winston-Salem, North Carolina · Completed

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Completed

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Completed

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • The Cleveland Clinic Foundation

    Lyndhurst, Ohio · Active not recruiting

  • University of Oklahoma - Health Sciences Center

    Oklahoma City, Oklahoma · Active not recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Active not recruiting

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.